These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

107 related items for PubMed ID: 1673051

  • 1. Double-blind placebo-controlled trial of buflomedil in the treatment of Raynaud's phenomenon: six-month follow-up.
    Le Quentrec P, Lefebvre ML.
    Angiology; 1991 Apr; 42(4):289-95. PubMed ID: 1673051
    [Abstract] [Full Text] [Related]

  • 2. Microcirculatory changes in patients with primary Raynaud's phenomenon after treatment with buflomedil.
    Jacobs MJ, Lemmens HA.
    Int J Microcirc Clin Exp; 1985 Apr; 4(1):63-8. PubMed ID: 3886577
    [Abstract] [Full Text] [Related]

  • 3. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo-controlled, dose-comparison study.
    Black CM, Halkier-Sørensen L, Belch JJ, Ullman S, Madhok R, Smit AJ, Banga JD, Watson HR.
    Br J Rheumatol; 1998 Sep; 37(9):952-60. PubMed ID: 9783759
    [Abstract] [Full Text] [Related]

  • 4. Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study.
    Wigley FM, Korn JH, Csuka ME, Medsger TA, Rothfield NF, Ellman M, Martin R, Collier DH, Weinstein A, Furst DE, Jimenez SA, Mayes MD, Merkel PA, Gruber B, Kaufman L, Varga J, Bell P, Kern J, Marrott P, White B, Simms RW, Phillips AC, Seibold JR.
    Arthritis Rheum; 1998 Apr; 41(4):670-7. PubMed ID: 9550476
    [Abstract] [Full Text] [Related]

  • 5. Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study.
    Limbs International Medicinal Buflomedil (LIMB) Study Group, Leizorovicz A, Becker F.
    Circulation; 2008 Feb 12; 117(6):816-22. PubMed ID: 18212283
    [Abstract] [Full Text] [Related]

  • 6. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy.
    Fries R, Shariat K, von Wilmowsky H, Böhm M.
    Circulation; 2005 Nov 08; 112(19):2980-5. PubMed ID: 16275885
    [Abstract] [Full Text] [Related]

  • 7. MQX-503, a novel formulation of nitroglycerin, improves the severity of Raynaud's phenomenon: a randomized, controlled trial.
    Chung L, Shapiro L, Fiorentino D, Baron M, Shanahan J, Sule S, Hsu V, Rothfield N, Steen V, Martin RW, Smith E, Mayes M, Simms R, Pope J, Kahaleh B, Csuka ME, Gruber B, Collier D, Sweiss N, Gilbert A, Dechow FJ, Gregory J, Wigley FM.
    Arthritis Rheum; 2009 Mar 08; 60(3):870-7. PubMed ID: 19248104
    [Abstract] [Full Text] [Related]

  • 8. Double-blind capillaroscopic study of the activity of buflomedil in Raynaud's syndrome: a report on 80 cases.
    Courbier R, Bergeron P, Fouque R.
    Angiology; 1981 Oct 08; 32(10):676-8. PubMed ID: 7325403
    [Abstract] [Full Text] [Related]

  • 9. A review of long-term safety data with buflomedil.
    Bachand RT, Dubourg AY.
    J Int Med Res; 1990 Oct 08; 18(3):245-52. PubMed ID: 2193838
    [Abstract] [Full Text] [Related]

  • 10. Anaphylactic reactions to buflomedil.
    Scala E, Guerra EC, Pirrotta L, Giani M, De Pità O, Puddu P.
    Allergy; 1999 Mar 08; 54(3):288-9. PubMed ID: 10321569
    [No Abstract] [Full Text] [Related]

  • 11. Enalapril in Raynaud's phenomenon.
    Janini SD, Scott DG, Coppock JS, Bacon PA, Kendall MJ.
    J Clin Pharm Ther; 1988 Apr 08; 13(2):145-50. PubMed ID: 2839529
    [Abstract] [Full Text] [Related]

  • 12. Nicardipine in the treatment of Raynaud's phenomenon: a randomized double-blind trial.
    Kahan A, Amor B, Menkès CJ, Weber S, Guérin F, Degeorges M.
    Angiology; 1987 Apr 08; 38(4):333-7. PubMed ID: 3555175
    [Abstract] [Full Text] [Related]

  • 13. Buflomedil in arterial occlusive disease: results of a controlled multicenter study.
    Trübestein G, Balzer K, Bisler H, Klüken N, Muller-Wiefel H, Unkel B, Mahfoud Y, Ziegler W.
    Angiology; 1984 Aug 08; 35(8):500-5. PubMed ID: 6383127
    [Abstract] [Full Text] [Related]

  • 14. Letter by De Backer et al regarding article, "Oral buflomedil in the prevention of cardiovascular events in patients with peripheral arterial obstructive disease: a randomized, placebo-controlled, 4-year study".
    De Backer TL, Vander Stichele RH, Van Bortel LM.
    Circulation; 2008 Sep 02; 118(10):e151. PubMed ID: 18765384
    [No Abstract] [Full Text] [Related]

  • 15. A double blind placebo controlled crossover randomized trial of diltiazem in Raynaud's phenomenon.
    Rhedda A, McCans J, Willan AR, Ford PM.
    J Rheumatol; 1985 Aug 02; 12(4):724-7. PubMed ID: 3903157
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Modified-release sildenafil reduces Raynaud's phenomenon attack frequency in limited cutaneous systemic sclerosis.
    Herrick AL, van den Hoogen F, Gabrielli A, Tamimi N, Reid C, O'Connell D, Vázquez-Abad MD, Denton CP.
    Arthritis Rheum; 2011 Mar 02; 63(3):775-82. PubMed ID: 21360507
    [Abstract] [Full Text] [Related]

  • 18. [Nicardipine in the treatment of Raynaud's phenomenon].
    Kahan A, Amor B, Menkès CJ.
    Rev Rhum Mal Osteoartic; 1987 Jun 02; 54(6):487-90. PubMed ID: 3303287
    [Abstract] [Full Text] [Related]

  • 19. Effect of buflomedil on behaviour, memory, and intellectual capacity in patients with dementia. A placebo-controlled study.
    Levinson B, Wright P, Barklem S.
    S Afr Med J; 1985 Aug 31; 68(5):302-7. PubMed ID: 3898413
    [Abstract] [Full Text] [Related]

  • 20. Multicentre clinical placebo-controlled study with buflomedil in the treatment of mild dementia of vascular origin.
    Cucinotta D, Aveni Casucci MA, Pedrazzi F, Ponari O, Capodaglio M, Valdina P, Toxiri I, Bartorelli L, Granata Q, Franzini C.
    J Int Med Res; 1992 Apr 31; 20(2):136-49. PubMed ID: 1521670
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.